CRNX
Crinetics Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$84.95
+0.00%Aug 3, 2026, 22:46 UTC
Crinetics Pharmaceuticals reported a second-quarter net loss of $1.14 per share, narrower than the Zacks Consensus Estimate of a $1.23 loss and improved from a $1.23 loss a year earlier.
Source:Jul 7, 2026, 00:00 UTC
Vertex Pharmaceuticals signed a merger agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, expected to close in Q3 2026.
Jun 14, 2026, 18:45 UTC
Crinetics Pharmaceuticals presented long-term clinical data for PALSONIFY (paltusotine) at ENDO 2026, demonstrating durable acromegaly control.